HDAC inhibiting derivatives of camptothecin
US8980909B2 · kind B2 · utility
1Cited by
3References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 6, 2012 |
| Grant date | Mar 17, 2015 |
| Priority date | — |
| Expiry date | Jan 6, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure includes hydroxamic compounds of Formula I: (Formula I) wherein Z, L, R1, R2, and R3 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.